AmTech, headquartered in Shenzhen, China, is an innovative high-tech enterprise founded in September 2017. AmTech specializes in the R&D and manufacturing of high-end IVD reagents (Enzymatic Assay, Immunoturbidimetric Assay, and Chemiluminescent Immunoassay), instruments and biological raw materials for clinical and research labs.

The mission of AmTech is to become a world first class biotech enterprise driven by innovation and make significant contribution to the development of science and technology in the world. With eight state-of-the-art technology platforms, we have built a solid foundation for breakthrough discoveries. Key among our technological advancements is the biomacromolecule point to point covalent bioconjugation platform, which forms the basis for developing high-quality products. Additionally, our tunable gene recombination platform serves as an essential tool for R&D and manufacturing of biological raw materials. So far, we have filed over 40 patents, with more than 20 successfully granted.

AmTech’s newest point to point covalent bioconjugation technology has been applied to our immunoturbidimetric assay products. This advanced method offers six distinct advantages：improving reagent sensitivity for highly accurate detection results, widening linearity range to reduce the hook effect, enhancing resistance to interference, minimizing product batch-to-batch difference, increasing coupling efficiency. Moreover, it significantly enhances reagent stability.